China Biologic Products (CBPO) Rating Lowered to Strong Sell at BidaskClub

China Biologic Products (NASDAQ:CBPO) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

CBPO has been the topic of a number of other reports. ValuEngine upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Zacks Investment Research lowered shares of China Biologic Products from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 9th. Finally, Credit Suisse Group lowered shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a research report on Monday, August 6th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. China Biologic Products has a consensus rating of “Hold” and an average price target of $101.00.

Shares of CBPO stock traded down $1.25 during trading hours on Friday, reaching $71.00. 152,000 shares of the company were exchanged, compared to its average volume of 298,931. China Biologic Products has a fifty-two week low of $70.65 and a fifty-two week high of $107.44. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of 14.34, a PEG ratio of 1.51 and a beta of 1.18.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Friday, August 3rd. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.26 by ($0.09). China Biologic Products had a return on equity of 14.00% and a net margin of 15.89%. The company had revenue of $120.40 million for the quarter, compared to analyst estimates of $116.21 million. During the same quarter in the previous year, the company posted $1.35 earnings per share. China Biologic Products’s revenue for the quarter was up 34.8% on a year-over-year basis. Equities research analysts anticipate that China Biologic Products will post 3.71 earnings per share for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Baillie Gifford & Co. raised its stake in shares of China Biologic Products by 0.7% during the second quarter. Baillie Gifford & Co. now owns 1,347,282 shares of the biopharmaceutical company’s stock worth $133,826,000 after buying an additional 8,968 shares during the last quarter. BlackRock Inc. raised its stake in shares of China Biologic Products by 36.5% during the first quarter. BlackRock Inc. now owns 926,412 shares of the biopharmaceutical company’s stock worth $75,038,000 after buying an additional 247,555 shares during the last quarter. Bank of America Corp DE raised its stake in shares of China Biologic Products by 19.8% during the second quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock worth $64,690,000 after buying an additional 107,573 shares during the last quarter. FMR LLC raised its stake in shares of China Biologic Products by 0.3% during the second quarter. FMR LLC now owns 234,100 shares of the biopharmaceutical company’s stock worth $23,253,000 after buying an additional 700 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of China Biologic Products by 10.7% during the second quarter. Renaissance Technologies LLC now owns 123,600 shares of the biopharmaceutical company’s stock worth $12,277,000 after buying an additional 11,900 shares during the last quarter. 44.23% of the stock is owned by institutional investors and hedge funds.

About China Biologic Products

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Story: Exchange-Traded Funds (ETFs)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply